Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.

Tinengotinib, a selective multi-kinase inhibitor, effectively targets FGFR2 fusion/rearrangement and resistance mutations in early trials involving cholangiocarcinoma patients.

CSL Reveals Key Findings of Phase 3 AEGIS-II Study Assessing Effectiveness and Security of CSL112 (Human Apolipoprotein A-I).

Clopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997.

Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.

Tasurgratinib (E7090) is an orally available selective inhibitor of FGFR 1–3, the recommended dose is 140 mg per day per the dose-escalation part of a first-in-human phase 1 study.

At the EAHAD Congress in 2024, Hemab Therapeutics Unveils Encouraging Initial Findings for Their Drug, HMB-001, Targeting Glanzmann's Thrombasthenia.

Hydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension.

Chugai Pharmaceutical announced that China's National Medical Products Administration approved its innovative C5 monoclonal antibody, crovalimab.

Colorectal cancer (CRC) ranks second in US cancer deaths. 5-fluorouracil (5-FU) therapies with targeted drugs are the go-to for advanced cases.

In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.

Oxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology.